<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/Boehringer11Dec25shutterstock_2381622677-3-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/Boehringer11Dec25shutterstock_2381622677-3-430x241.jpg"/>
                                    
                                    <figcaption>The therapy offers a new alternative for the life-threatening lung condition. Credit: pada smith stockphoto/Shutterstock.com.</figcaption>
                                </figure>
                            </div>
                                             
     
<p>China’s National Medical Products Administration (NMPA) has granted approval for Boehringer Ingelheim’s Jascayd (nerandomilast) to treat progressive pulmonary fibrosis (PPF).</p>



<p>The approval marks the first new treatment for the adult population with PPF in more than five years, offering a new alternative for those with this life-threatening lung condition.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - Zilurgisertib Fumarate in Fibrodysplasia Ossif... </h4></div> </li><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - CC-90001 in Head And Neck Cancer Squamous Cell... </h4></div> </li></ul> <div>
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>The therapy is the sole preferential phosphodiesterase 4B (PDE4B) inhibitor with vascular, immunomodulatory and antifibrotic properties to be approved for this condition.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>The approval is supported by outcomes from the pivotal Phase III FIBRONEER-ILD trial, which demonstrated that nerandomilast met its main goal: the absolute change from baseline in forced vital capacity (FVC) [mL] at week 52 compared to placebo.</p>



<p>FVC is a critical measure of the function of the lungs, and findings from the trial indicate that nerandomilast slows the lung function decline in patients with PPF.</p>



<p>The therapy also showed favourable safety and tolerability, with low rates of discontinuation eliminating the need for monitoring of the liver.</p><div> 
                         <div>


            <div>

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div>

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<p>The FIBRONEER-ILD study showed that the therapy improved survival, with a significant decrease in mortality risk.</p>



<p>Boehringer Ingelheim human pharma head and managing directors’ board chairman Shashank Deshpande stated: “For the first time, people living with PPF will have access to a new treatment option for this progressive and life-threatening condition – a major advancement in a field where innovation has been scarce.</p><div id="slot-two"></div>



<p>“While this initial approval in China represents a pivotal milestone for the PPF community, we are working tirelessly to ensure patients around the world can benefit from Jascayd as quickly as possible.”</p>



<p>The PPF approval in China comes weeks after its approval by the Chinese regulator for idiopathic pulmonary fibrosis (IPF).</p>



<p>The US Food and Drug Administration has also approved nerandomilast for IPF after granting it priority review and breakthrough therapy statuses.</p>



<p>It is currently conducting a priority review for the therapy’s use in adults with PPF.</p>



<p>Regulatory submissions for the therapy in PPF and IPF are being reviewed in the European Union, Japan, the UK and other nations, with further clearances expected in 2026.</p>



<p>In November 2025, Boehringer and CDR-Life announced a global licensing agreement for the development of CDR111, an antibody-based molecule targeting autoimmune conditions.</p>
<div id="slot-three"></div><p></p>



<div>
    
</div>



                   
               <div>
                 <h2>Pharmaceutical Technology Excellence Awards - Nominations Closed</h2>
                 <p>Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.
<br/>
<br/>
<strong>Excellence in Action</strong>
<br/>Imagene’s Oncology Intelligence (OI) Suite  has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.</p>
Discover the Impact

             </div>

<p>China's NMPA has approved Boehringer Ingelheim's Jascayd (nerandomilast) for treating progressive pulmonary fibrosis (PPF). This marks the first new treatment for PPF in over five years. The approval is based on the successful Phase III FIBRONEER-ILD trial, which showed that nerandomilast slows lung function decline and improves survival. The therapy is the only PDE4B inhibitor approved for PPF, with favorable safety and tolerability. Regulatory submissions are also under review in the US, EU, Japan, and other countries.</p>

Boehringer’s Jascayd gains China’s NMPA approval for PPF